EMEA-001095-PIP03-19

Table of contents

Key facts

Invented name
Tysabri
Active substance
natalizumab
Therapeutic area
Neurology
Decision number
P/0123/2020
PIP number
EMEA-001095-PIP03-19
Pharmaceutical form(s)
Solution for injection in pre-filled syringe
Condition(s) / indication(s)
Treatment of multiple sclerosis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Biogen Idec Ltd

Tel. +44 (0)1628 501000
E-mail: pip.enquiries@biogen.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating